Patents by Inventor Eduardo LABORDA

Eduardo LABORDA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Switchable Chimeric Antigen Receptor-Engineered Human Natural Killer Cells
    Publication number: 20220152110
    Abstract: Engineered natural killer cells with switchable chimeric antigen receptor, methods of manufacture, pharmaceutical compositions, and methods of use in treating cancer and viral infection.
    Type: Application
    Filed: March 23, 2020
    Publication date: May 19, 2022
    Inventors: Dan S. Kaufman, Xiao-Hua Li, Eduardo Laborda, Travis Young
  • CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF
    Publication number: 20220073597
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Application
    Filed: August 30, 2021
    Publication date: March 10, 2022
    Inventors: Travis S. YOUNG, Leonard PRESTA, David RODGERS, Eric HAMPTON, Timothy WRIGHT, Peter G. SCHULTZ, Eduardo LABORDA, Elvira KHIALEEVA, Sophie VIAUD
  • Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
    Patent number: 11174306
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 16, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis S. Young, Leonard Presta, David Rodgers, Eric Hampton, Timothy Wright, Peter G. Schultz, Eduardo Laborda, Elvira Khialeeva, Sophie Viaud
  • Optimized PNE-based chimeric receptor T cell switches and uses thereof
    Patent number: 11091546
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 17, 2021
    Assignee: The Scripps Research Institute
    Inventors: Travis Young, David T. Rodgers, Ian Hardy, Chanhyuk Kim, Peter G. Schultz, Eric Hampton, Eduardo Laborda, Leonard Presta
  • CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF
    Publication number: 20190359697
    Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.
    Type: Application
    Filed: October 19, 2017
    Publication date: November 28, 2019
    Inventors: Travis S. YOUNG, Leonard PRESTA, David RODGERS, Eric HAMPTON, Timothy WRIGHT, Peter G. SCHULTZ, Eduardo LABORDA, Elvira KHIALEEVA, Sophie VIAUD
  • OPTIMIZED PNE-BASED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
    Publication number: 20190169289
    Abstract: Disclosed herein are chimeric antigen receptor effector cells (CAR-ECs) and CAR-EC switches. The switchable CAR-ECs are generally T cells. The one or more chimeric antigen receptors may recognize a peptidic antigen on the CAR-EC switch. The CAR-ECs and switches may be used for the treatment of a condition in a subject in need thereof.
    Type: Application
    Filed: April 15, 2016
    Publication date: June 6, 2019
    Inventors: Travis YOUNG, David T. RODGERS, Ian HARDY, Chanhyuk KIM, Peter G. SCHULTZ, Eric HAMPTON, Eduardo LABORDA, Leonard PRESTA
  • OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
    Publication number: 20180100026
    Abstract: Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain (TID). The switch may further comprise a linker. Further disclosed herein are methods of using the switches for the treatment of one or more conditions or diseases in a subject in need thereof.
    Type: Application
    Filed: April 15, 2016
    Publication date: April 12, 2018
    Inventors: Chanhyuk KIM, Travis YOUNG, Jennifer MA, Ji Young KIM, Xinxin WANG, Eduardo LABORDA, Peter G. SCHULTZ